Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CHUK | O15111 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | LTK | P29376 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | PRKX | P51817 | 1/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.63 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.63 |
| ▸ | STK3 | Q13188 | 1/20 | 0.63 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800289 | 0.85 | ALDH1A1 (0.66) | GLAKMT2AMEN1PTPN1ALDH1A1 | |
| SCHEMBL1553445 | 0.84 | ROCK2 (0.62) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL2467822 | 0.81 | NAMPT (0.67) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL30828553 | 0.81 | ROCK2 (0.76) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL7520976 | 0.81 | ROCK2 (0.76) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| Hydrochloric Acid SCHEMBL27545321 | 0.80 | ROCK2 (0.73) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL13006873 | 0.80 | ALDH1A1 (0.58) | TSHRMAPK1KMT2ANAMPTALDH1A1 | |
| SCHEMBL14492963 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL26318537 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1PKN2RPS6KA5LRRK2 | |
| SCHEMBL1552919 | 0.78 | TDP1 (0.61) | ROCK2ROCK1PKN2RPS6KA5LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | ROCK2 90/4885ROCK1 186/4885PKN2 1630/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | ROCK2 4/4885ROCK1 1/4885PKN2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.